EFFICACY OF A SUBUNIT APP VACCINE (PLEUROSTAR~(TM)4): A FIELD TRIAL IN THAILAND

摘要

Actinobacillus pleuropneumoniae (APP) is a causative agent of swine pleuropneumonia causing death losses, poor production, and increase costs of medication. APP-infected pigs may develop severe acute fibrinohemorrhagic pneumonia or chronic localized necrotizing pneumonia. In Thailand, serotypes 1,2, 3, and 5 has been reported to cause pneumonic lesions in 5 different farms based on rapid plate agglutination and agar gel diffusion tests. Currently, it is possible to prevent infection by the use of vaccines. The efficacy of currently available APP vaccines in Thailand yielded inconclusive results in the field, although experimental challenge yielded satisfactory results. Pleuro-Star~(TM) 4 (Biostar Inc., Saskatoon, Saskatchewan) is a pentavalent vaccine consisting of serotype 1 antigens (OmlA and CystI), serotype 5 antigen (Oml A), and serotype 7 antigens (CystA and TfbA) of APP using Emulsigen Plus as an adjuvant. The objective of this study is to determine the efficacy of a subunit APP vaccine (Pleuro-Star~(TM) 4) in 2 selected swine herds, which have serious experiences with APP outbreaks in the past 12 months in Thailand.